Integrin αvβ3-targeted imaging of lung cancer

Neoplasia

Volumn 7, Issue 3, 2005, Pages 271-279

  Chen, Xiaoyuan ^a,b   Sievers, Eric ^c   Hou, Yingping ^b   Park, Ryan ^a   Tohme, Michel ^a   Bart, Robert ^c   Bremner, Ross ^c   Bading, James R ^a   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Dimeric RGD peptide; Integrin v 3; Lung cancer; Metastasis; Positron emission tomography (PET)

Indexed keywords

ALPHA4 BETA3 INTEGRIN; ALPHA4 INTEGRIN; ARGININE; CELL ADHESION MOLECULE; FLUORODEOXYGLUCOSE; LIGAND; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CREATININE CLEARANCE; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; GENE TARGETING; IMAGE ANALYSIS; LUNG CANCER; METASTASIS; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR BINDING; TISSUE SPECIFICITY;

EID: 15744406017     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04538     Document Type: Article

References (43)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, and Thun MJ (2004). Cancer statistics, 2004. CA Cancer J Clin 54, 8-29.
2. Mulshine JL, Cuttitta F, Tookman MS, and De Luoa LM (2002). Lung cancer evolution to pre-invasive management. Clin Chest Med 23, 37-48.
3. Park BJ and Altorki NK (2002). Diagnosis and management of early lung cancer. Surg Clin North Am 82, 457-476.
4. Spira A and Ettinger DS (2004). Multidisciplinary management of lung cancer. N Engl J Med 350, 379-392.
5. Danesi R, de Braud F, Fogli S, de Pas TM, Di Paolo A, Curigliano G, and Del Tacca M (2003). Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 55, 57-103.
6. Sandler AB (2003). Molecular targeted agents in non-small-cell lung cancer. Clin Lung Cancer 5, S22-S28.
7. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, and Hartwell L (2003). The case for early detection. Nat Rev Cancer 3, 243-252.
8. Line BR and White CS (2004). Positron emission tomography scanning for the diagnosis and management of lung cancer. Curr Treat Options Oncol 5, 63-73.
9. Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME, Gambhir SS, Rao J, Valk PE, and Czernin J (2002). The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med 43, 752-756.
10. Rohren EM, Turkington TG, and Coleman RE (2004). Clinical applications of PET in oncology. Radiology 231, 305-332.
11. Weber V, Petersen WA, Schmidt B, Tyndale-Hines L, Link T, Peschel C, and Schwaiger M (2003). Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21, 2651-2667.
12. Kirsch M, Schackert G, and Black PM (2004). Metastasis and angiogenesis. Cancer Treat Res 117, 285-304.
13. Kerbel RS (2004). Antiangiogenic drugs and current strategies for the treatment of lung cancer. Semin Oncol 31, 54-60.
14. Strieter RM, Belperio JA, Phillips RJ, and Keane MP (2004). Chemokines: angiogenesis and metastases in lung cancer. Novartis Found Symp 256, 173-184.
15. Smythe WR, LeBel E, Bavaria JE, Kaiser LR, and Albelda SM (1995). Integrin expression in non-small cell carcinoma of the lung. Cancer Metastasis Rev 14, 229-239.
16. v Integrin inhibitors and cancer therapy. Curr Opin Invest Drugs 4, 722-731.
17. 3. Q J Nucl Med 47, 209-220.
18. 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4, 123-131.
19. Haubner RH, Wester HJ, Weber WA, and Schwaiger M (2003). Radiotracer-based strategies to image angiogenesis. Q J Nucl Med 47, 189-199.
20. 3-targeted magnetic resonance imaging. Nat Med 4, 623-626.
21. 3-targeted nanoparticles. Magn Reson Med 44, 433-439.
22. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 31, 179-189.
23. 64Cu-labeled RGD peptide. Bioconjug Chem 15, 41-49.
24. 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31, 11-19.
25. 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 31, 1081-1089.
26. 18F-labeled dimeric RGD peptide. Mol Imaging 3, 96-104.
27. 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 6, 350-359.
28. 3 expression. J Nucl Med 45, 1776-1783.
29. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15, 61-69.
30. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61, 1781-1785.
31. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, and Schwaiger M (2001). Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42, 326-336.
32. 3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 40, 1061-1071.
33. Janssen M, Oyen WJ, Massuger LF, Frielink C, Dijkgraaf I, Edwards DS, Radjopadhye M, Corstens FH, and Boerman OC (2002). Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 17, 641-646.
34. 3 integrin binding peptides in a nude mouse model. Cancer Res 62, 6146-6151.
35. van Hagen PM, Breeman WA, Bernard HF, Schaar M, Mooij CM, Srinivasan A, Schmidt MA, Krenning EP, and de Jong M (2000). Evaluation of a radiolabeled cyclic DTPA-RGD analogue for tumor imaging and radionuclide therapy. Int J Cancer 90, 186-198.
36. 3. Circulation 108, 336-341.
37. 64Cu using a biomedical cyclotron. Nucl Med Biol 24, 35-43.
38. 3 receptor. J Pharmacol Exp Ther 283, 843-853.
39. Diperna CA, Bart RD, Sievers EM, Ma Y, Starnes VA, and Bremner RM (2003). Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. J Thorac Cardiovasc Surg 126, 1129-1133.
40. Qi J, Leahy RM, Cherry SR, Chatziioannou A, and Farquhar TH (1998). High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner. Phys Med Biol 43, 1001-1013.
41. 3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 45, 1390-1397.
42. Wary KK (2004). Molecular targets for anti-angiogenic therapy. Curr Opin Mol Ther 6, 54-70.
43. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, and Gasparini G (2002). Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 5, 237-256.